These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7990527)

  • 1. [Recombinant factor VIII. An introduction to recombinant DNA technology and the first results published in the replacement treatment of hemophilia A].
    Juárez Giménez JC; Montoro Ronsano JB; Tusell JM
    Med Clin (Barc); 1994 Nov; 103(15):591-5. PubMed ID: 7990527
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.
    Lusher JM
    Vox Sang; 1999; 77 Suppl 1():9. PubMed ID: 10529677
    [No Abstract]   [Full Text] [Related]  

  • 3. Who should receive recombinant factor VIII?
    Giangrande PL
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant factor VIII in hemophilia.
    Cohen A; Butler R
    N Engl J Med; 1991 May; 324(21):1515-6. PubMed ID: 1902552
    [No Abstract]   [Full Text] [Related]  

  • 6. Development and introduction of recombinant factor VIII--a clinician's experience.
    Lusher JM
    Haemophilia; 2012 Jul; 18(4):483-6. PubMed ID: 22512315
    [No Abstract]   [Full Text] [Related]  

  • 7. Factor VIII inhibitor and severity of hemophilia.
    Schoppmann A; Waytes AT
    Thromb Haemost; 1996 Aug; 76(2):280-1. PubMed ID: 8865549
    [No Abstract]   [Full Text] [Related]  

  • 8. Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience.
    Afonja O; Kozak R; Petraro P; Michaels LA; Mathew P; Lemm G; Kessler C
    Expert Rev Hematol; 2016 Dec; 9(12):1151-1164. PubMed ID: 27841041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophilia market awaits next-generation therapies.
    Sheridan C
    Nat Biotechnol; 2011 Nov; 29(11):960. PubMed ID: 22068523
    [No Abstract]   [Full Text] [Related]  

  • 10. Bioengineered Factor VIII - More Innovation for Hemophilia A.
    Chowdary P
    N Engl J Med; 2024 Jul; 391(3):277-282. PubMed ID: 39018538
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of recombinant factor VIII in the management of hemophilia.
    Mannucci PM; Gringeri A; Cattaneo M
    Curr Stud Hematol Blood Transfus; 1991; (58):46-51. PubMed ID: 1954773
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunogenicity of factor VIII concentrates in patients with hemophilia: a randomized clinical trial is warranted.
    Gringeri A; Mannucci PM
    Blood; 2007 Oct; 110(8):3084; author reply 3085. PubMed ID: 17916754
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII.
    Bray G
    Ann Hematol; 1994; 68 Suppl 3():S29-34. PubMed ID: 8180254
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of recombinant factor VIII in the management of hemophilia.
    Mannucci PM; Gringeri A
    Ric Clin Lab; 1991; 21(1):1-7. PubMed ID: 1907760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials of the recombinant factor VIII product, Kogenate.
    Inwood M; Lusher J
    Transfus Med Rev; 1992 Oct; 6(4):261-2. PubMed ID: 1421826
    [No Abstract]   [Full Text] [Related]  

  • 16. Psychosocial issues surrounding the general or restricted use of recombinant factor VIII: hemophilia clinic perspective.
    McDonald JR
    Transfus Med Rev; 1992 Oct; 6(4):277-9. PubMed ID: 1421829
    [No Abstract]   [Full Text] [Related]  

  • 17. The past and the future: recombinant factor VIII and the consumer.
    Isaac BM
    Transfus Med Rev; 1992 Oct; 6(4):280-3. PubMed ID: 1421830
    [No Abstract]   [Full Text] [Related]  

  • 18. Laboratory monitoring issues in recombinant porcine FVIII replacement in acquired haemophilia A.
    Vanguru VR; Kershaw G; Konda M; Chen VM
    Haemophilia; 2018 Mar; 24(2):e70-e74. PubMed ID: 29418045
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
    Musso R
    Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment for hemophilia.
    FDA Consum; 2003; 37(6):5. PubMed ID: 14983810
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.